Oncology

Target Validation

Epistem offers a range of in vitro options for assessment of pre-clinical novel therapeutic agents including target expression, pathway analysis and cytotoxicity assays. Cancer stem cell and angiogenesis assays provide more in-depth readouts of efficacy.

Target Validation

The first step in assessing efficacy must be selection of the appropriate models. Epistem can assist in the selection of appropriate cell lines and tumour types by evaluating target expression levels. Target expression can be quantified by immunohistochemistry with image analysis or by gene expression profiling. Epistem's proprietary gene expression technology enables analysis of very small amounts of starting material, whether cultured cells or areas isolated from diseased tissue by laser capture microdissection.

In Vitro Cytotoxicity

Epistem provides a range of standard in vitro cytotoxicity assays. These assays can be carried out in a wide range of human tumour cell lines, many of which have also been validated in subcutaneous xenografts.

Readouts

  • IC50 and EC50 doses
  • Viable cell number, proliferation and apoptosis
  • FACS analysis of target expression
  • Gene expression analysis of target effects

Image generated using the Acumen Explorer(R) showing a reduction of confluence of HCT 116 cells observed in a cytotoxicity assay

Image generated using the Acumen Explorer® showing a reduction of confluence of HCT 116 cells observed in a cytotoxicity assay

© 2013-17 Epistem Ltd. : : last modified: 04 Nov 2013

Epistem Ltd is a division of genedrive plc